The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Self-citationThe Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J.-P., Cervantes, G., Fumoleau, P., Jones, S., Lui, W.-Y., Mauriac, L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.002 · Cited by 1,081
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Greenberg, P. A., Hortobagyi, G. N., Smith, T. L., Ziegler, L. D., Frye, D. K., & Buzdar, A. U. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2197 · Cited by 738
Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., Flockhart, D. A., Hancock, B., Davidson, N., Gralow, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604
Molecular Stratification of Triple-Negative Breast Cancers
Perou, C. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-61 · Cited by 582
Pattern of metastatic spread in triple-negative breast cancer
Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0086-2 · Cited by 554
Breast cancer as a global health concern
Coughlin, S. S., & Ekwueme, D. U. (2009) · Cancer Epidemiology · doi:10.1016/j.canep.2009.10.003 · Cited by 523
Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., Mierzwa, T., Szwiec, M., Wiśniowski, R., Siolek, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7019 · Cited by 516
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., Brunet, J.-S., Akslen, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2132 · Cited by 489
Burstein, H. J., Elias, A. D., Rugo, H. S., Cobleigh, M. A., Wolff, A. C., Eisenberg, P. D., Lehman, M., Adams, B. J., Bello, C. L., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5375 · Cited by 489
Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 481
Kassam, F., Enright, K., Dent, R., Dranitsaris, G., Myers, J., Flynn, C., Fralick, M., Kumar, R., & Clemons, M. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.005 · Cited by 474
Thomas, E. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5019 · Cited by 428
Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents
Isakoff, S. J. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181d24ff7 · Cited by 348
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348
Andre, F., Job, B., Dessen, P., Tordai, A., Michiels, S., Liedtke, C., Richon, C., Yan, K., Wang, B., Vassal, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1791 · Cited by 336
Thomas, E., Tabernero, J., Fornier, M., Conté, P., Fumoleau, P., Lluch, A., Vahdat, L. T., Bunnell, C. A., Burris, H. A., Viens, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9102 · Cited by 290
Leong, C.-O., Vidnovic, N., DeYoung, M. P., Sgroi, D., & Ellisen, L. W. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30866 · Cited by 270
Third consensus on medical treatment of metastatic breast cancer
Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp261 · Cited by 263
Self-citationA Review of Triple-Negative Breast Cancer
Ismail-Khan, R., & Bui, M. M. (2010) · Cancer Control · doi:10.1177/107327481001700305 · Cited by 254
Cardoso, F., Bedard, P. L., Winer, E. P., Pagani, O., Senkus-Konefka, E., Fallowfield, L. J., Kyriakides, S., Costa, A., Cufer, T., Albain, K. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp235 · Cited by 241
Chacón, R. D., & Costanzo, M. V. (2010) · Breast Cancer Research · doi:10.1186/bcr2574 · Cited by 239
Molecular Stratification of Triple-Negative Breast Cancers
Perou, C. M. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-s5-39 · Cited by 203
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
Bernard-Marty, C., Cardoso, F., & Piccart, M. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-617 · Cited by 177
Carey, L. A., Rugo, H. S., Marcom, P. K., Irvin, W., Ferraro, M., Burrows, E., He, X., Perou, C. M., & Winer, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1009 · Cited by 163
Biomarkers and Multiple Drug Resistance in Breast Cancer
O’Driscoll, L., & CLYNES, M. M. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906777723958 · Cited by 128
Sparano, J. A., Makhson, A. N., Семиглазов, В. Ф., Tjulandin, S., Balashova, O. I., Bondarenko, I., Bogdanova, N. V., Manikhas, G. M., Oliynychenko, G. P., Chatikhine, V. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5013 · Cited by 116
O’Shaughnessy, J., Miles, D., Gray, R. J., Dieras, V. C., Perez, E. A., Zon, R. T., Cortés, J., Zhou, X., Phan, S.-C., & Miller, K. D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.1005 · Cited by 111
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
Perez, E. A., Patel, T., & Moreno‐Aspitia, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0824-0 · Cited by 90
EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer
Nogi (1994) · Oncology Reports · doi:10.3892/or_00000238 · Cited by 85
Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy
Ryan, P. D., Tung, N., Isakoff, S. J., Golshan, M. A., Richardson, A., Corben, A. D., Smith, B. L., Gelman, R. S., Winer, E. P., & Garber, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.551 · Cited by 82
Koshy, N. V., Quispe, D., Shi, R., Mansour, R. P., & Burton, G. V. (2010) · The Breast · doi:10.1016/j.breast.2010.02.003 · Cited by 79
Farquhar, C. M., Marjoribanks, J., Basser, R. L., et al. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003142.pub2 · Cited by 79
Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors
Rivera, E., Lee, J., & Davies, A. M. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0143 · Cited by 79
Uhm, J. E., Park, Y. H., Yi, S. Y., Cho, E. Y., Choi, Y., Lee, S. J., Park, M. J., Lee, S., Jun, H. J., Ahn, J. S., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24090 · Cited by 72
Rechallenging with anthracyclines and taxanes in metastatic breast cancer
Palmieri, C., Krell, J., James, C. R., Harper-Wynne, C. L., Misra, V., Cleator, S. J., & Miles, D. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.122 · Cited by 67
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Gronwald, J., Byrski, T., Huzarski, T., Dent, R. A., Bielicka, V., Zuziak, D., Wiśniowski, R., Lubiński, J., & Narod, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.502 · Cited by 61
Lehmann‐Che, J., André, F., Desmedt, C., Mazouni, C., Giacchetti, S., Turpin, E., Espié, M., Plassa, L., Marty, M. E., Bertheau, P., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0243 · Cited by 56
Self-citationBaselga, J. M., Stemmer, S. M., Pêgo, A., Chan, A., Goeminne, J.-C., Graas, M. P., Kennedy, J. F., Gil, E. C., Zubel, A., Groos, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-pd01-01 · Cited by 49
Rugo, H. S., Roche, H. H., Thomas, E., Blackwell, K., Chung, H., Lerzo, G. L., Volles, L., Poulart, V., & Perez, E. A. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-3057 · Cited by 46
Stemmler, H., Gioia, D. D., Freier, W., Tessen, H. W., Gitsch, G., Jonat, W., Brugger, W., Kettner, E., Abenhardt, W., Tesch, H., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.86 · Cited by 40
Triple-negative breast cancer: a clinical update
Cleere, D. W. (2010) · Community Oncology · doi:10.1016/s1548-5315(11)70394-1 · Cited by 36
Nieto, Y. L., & Shpall, E. J. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328324f48b · Cited by 28
Leone, J. P., Guardiola, V., Venkatraman, A., Pegram, M. D., Welsh, C. F., Silva, O., Larrieux, R., Franchesci, D., Gómez, C., & Hurley, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.625 · Cited by 22
Cited by
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Dirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.-T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 746
Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis
Jolly, M. K. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00155 · Cited by 693
Bardia, A., Mayer, I. A., Diamond, J. R., Moroose, R. L., Isakoff, S. J., Starodub, A. N., Shah, N. C., O’Shaughnessy, J., Kalinsky, K., Guarino, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8297 · Cited by 412
Breast Cancer Metastasis: Mechanisms and Therapeutic Implications
Park, M., Kim, D., Ko, S., Kim, A., Mo, K., & Yoon, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126806 · Cited by 406
Metadata
- Authors
- André, F., & Zielinski, C. C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 23
- Pages
- vi46-vi51
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2135601011
- Cited by
- 329
- References
- 53
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.